BioCryst Pharmaceuticals
BioCryst Pharmaceuticals

BioCryst Pharmaceuticals

Biotechnology
WebsiteInvestor RelationsSEC
BioCryst Pharmaceuticals Inc is a biotechnology company involved mainly in the research and development of novel small-molecule drugs, to block key enzymes involved in infectious and inflammatory diseases. Biocryst's research is based on multiple scientific disciplines like biology, computer modeling, and medicinal chemistry. Its products and candidates target the following therapeutic areas: acute uncomplicated influenza; uncomplicated seasonal influenza; hereditary angioedema; filoviruses, including the Ebola and Marburg viruses; and oncology.

$2.2B

Market Cap • 10/9/2026

1991

(35 years)

Founded

1994

(32 years ago)

IPO

NASDAQ

Listing Exchange

Flag of United States

United States

Country

Valuation

P/B

—

P/S

2,3

P/EBITDA

—

P/OCF

5,8

P/FCF

5,9

P/E

—

BVPS

—

EPS

—

Market Cap

Market Cap

2,2B

EV

2,7B

EV/Revenue

2,9

EV/EBITDA

-8,6

EV/EBIT

-8,6

Payout

Dividend Per Share

0

Dividend Yield

0%

Buyback Yield

-0,8%

Total Yield

-0,8%

Payout

0%

Retained Earnings

-2,1B

Profitability

Gross Margin

97,8%

EBITDA Margin

—

EBIT Margin

—

Net Margin

—

D&A/EBITDA

0%

R&D/Revenue

21%

Capex/Revenue

0,3%

Capex/D&A

119,8%

Capex/OCF

0,7%

SBC/OCF

19,4%

% PPE

3,9%

% Goodwill

0%

ROE

87,8%

ROIC

—

Growth

CAGR Revenue 5Y

64,1%

CAGR Op. Income 5Y

12,2%

CAGR Net Income 5Y

12,4%

CAGR EPS 5Y

4,6%

Leverage

N.D./EBITDA

—

Debt/Equity

0%

Current Ratio

2,3

Quick Ratio

2,2

Interest Coverage

—

Premium

Unlock 100% of the data and have immediate access on more than 6.000 companies with updated information!
  • Unrestricted access
  • Unlimited data history
  • Analysis videos
  • Quarterly highlights
  • Customizable financials table
  • Ranking
  • Discussions

...and much more!

Get Premium